Navigation Links
Herceptin and chemo improves response rates without major adverse effects in HER2 breast cancer
Date:4/18/2008

Berlin, Germany: Women with a particularly aggressive form of breast cancer seem to do better if they are treated with a combined anthracycline and taxane chemotherapy regimen before surgery, together with trastuzumab (Herceptin) before and after surgery, according to results from the largest multi-centre trial to investigate this treatment.

Professor Michael Untch told the 6th European Breast Cancer Conference (EBCC-6) in Berlin today (Friday) that the women in the trial did not suffer from any serious side effects of the treatment such as severe heart problems. These results are very challenging, as both trastuzumab and anthracyclines are associated with cardiac toxicity.

Prof Untch said: When we started this trial it was considered very courageous to give patients anthracyclines plus trastuzumab, but we wanted to expose patients to trastuzumab for as long as possible before surgery to make it as effective as possible. To minimise the risk, we excluded patients with any previous heart problems and excluded patients with ejection fractions of below 55%. However, our results showed no increase in toxicity for the combination chemotherapy plus trastuzumab compared with chemotherapy alone. There were no cases of congestive heart failure or cardiac-related deaths, and other cardiac-related symptoms were not severe. The combination chemotherapy plus trastuzumab proved to be the most effective combination, but, at the same time, we have to keep an eye on the heart. Therefore, cardiac monitoring every three months is a must for patients treated with this regimen.

A total of 1510 breast cancer patients were recruited to the GeparQuattro trial between 2006-2007; 453 of them had tumours that over-expressed the HER2 receptor (a particularly aggressive form of the disease). Before surgery they received four cycles of epirubicin/cyclophosphamide (EC) and were then randomised to receive either four cycles of docetaxel (D) or four cycles of D-capec
'/>"/>

Contact: Emma Mason
wordmason@mac.com
ECCO-the European CanCer Organisation
Source:Eurekalert

0

GOOD

Page: 1 2

Related biology news :

1. UC health news: molecular pathway may predict chemotherapy effectiveness
2. A search for protection against chemotherapy cardiotoxicity
3. Standard chemo works better against metastatic BRCA1/2 breast cancer than against sporadic tumors
4. New chemotherapy combo produces side effects, but no extra efficacy, in early breast cancer patients
5. Exercise improves thinking, reduces diabetes risk in overweight children
6. Endobronchial valve significantly improves emphysema
7. Teamwork improves learning and career success
8. New clinical data shows chromium picolinate improves cognitive function
9. Stem-cell transplantation improves muscles in MD animal model, UT Southwestern researchers report
10. Key to out-of-control immune response in lung injury found
11. Flies can turn off their immune response

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...upus Research Institute (LRI) today named 12 new g...6 million, recognize innovative work across a broa...r their creativity, novelty, and potential to driv...t, and cure the complex disease of systemic lupus....d lupus researchers across the nation and include ...
(Date:11/24/2009)...tists have crystallised a protein that may help gu... protein could be used by probiotic producers to i...fit to people. , "Probiotics need to interact wit..., and if they attach to surfaces in the gut they a...t their activity," says Dr Nathalie Juge from the ...
(Date:11/24/2009)...tomic-level action of a remarkable class of ring-s...hers with the Lawrence Berkeley National Laborator...crystallography beamline at the Advanced Light Sou... in gene expression and replication, and are vital...as infectious agents, such as the human papillomav...
Breaking Biology News(10 mins):Lupus Research Institute announces 2009 novel research grants 2Lupus Research Institute announces 2009 novel research grants 3A sticky solution for identifying effective probiotics 2Atomic-level snapshot catches protein motor in action 2Atomic-level snapshot catches protein motor in action 3Atomic-level snapshot catches protein motor in action 4Michigan Society for Healthcare Planning and Marketing to Hold Fall Conference 58979 1FlowCardia Inc Launches FlowMate 28TM 29 Injector to Optimize Performance of CROSSER 28R 29 CTO Recanalization Catheter 58974 1FlowCardia Inc Launches FlowMate 28TM 29 Injector to Optimize Performance of CROSSER 28R 29 CTO Recanalization Catheter 58974 2Leafy Greens Top Risky Food List 58971 1Leafy Greens Top Risky Food List 58971 2
...n improved technique for culturing cells, develope...ology (NIST), may enable new, fundamental insights...particular types of cells in isolation is a basic ...s stimuli, testing new drugs, and similar cell bio...ral nervous system in mammals, are both particular...
...he ubiquitous bacteria E. coli rank among nature,s...hich biologists at the University of Southern Cali... feast on the DNA of their dead competitors. , A r...ssor of molecular and computational biology in the...ready shown that DNA is an acceptable source of nu...
...esearchers at Purdue University have developed a n...ight to quickly identify bacteria for applications...y at one-tenth the cost of conventional technologi...ing Optical Scattering Technology - works by shini...al colonies growing in a nutrient medium. , "Unl...
Other Biology News:Neuronal cell cultures kept on the straight and narrow 2DNA: Bacteria's survival ration 2Purdue creates new low-cost system to detect bacteria 2Purdue creates new low-cost system to detect bacteria 3Purdue creates new low-cost system to detect bacteria 4
(Date:11/24/2009)...vember24/PRNewswire-FirstCall/--deCODE,genetics,In...ts,"firstday"motionsbytheU.S.BankruptcyCourtforthe...stweekfiledavoluntarypetitionfor,reliefunderChapte...cyCourt. , TheordersissuedbytheBankruptcyCour...ingtheChapter11proceedings.Inparticular,the,compan...
(Date:11/24/2009)...wswire-Asia/--ShanghaiBiolaxyannouncedthe,ChineseS...e,investigationalnewdrugapplication(IND)foritsoral...tiontotreatdiabetes.ThisIND,approvalallowsBiolaxyt...tesisadisordercharacteristicofhighbloodglucoseandp...ltinseveremicro-and,macro-vasculardiseases,lossofv...
(Date:11/24/2009)...inthasbeenmetforpatientswithadvanced-stage,orrecur...Newswire-FirstCall/-AEternaZentarisInc.(NASDAQ: AE...lcompanyfocusedonendocrinetherapyandoncology,today...tstargetedcytotoxicpeptideconjugate,AEZS-108(forme...trialcancer.Inapersonalizedhealthcareapproach,thes...
(Date:11/24/2009).../PRNewswire-FirstCall/--ArenaPharmaceuticals,Inc.(...duledtopresentatthePiperJaffray21stAnnualHealthCar...8:30a.m.PacificTime)attheNewYorkPalaceHotelinNewYo...eOfficer,isscheduledtoprovideanoverviewofthecompan...ams. ,, Aliveaudiowebcastofthepresentationwillb...
Breaking Biology Technology:deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 2deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 3Biolaxy Secures IND Approval for Oral Insulin 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 2
... Merge Technologies, Inc. , a developer and prov... software and services, announced its second quart...d losses. , ,Although quarterly revenue was at a r...ss of slightly under $12 million, or $0.62 per sha...fter acquiring Cedara Software, Inc. , a medical ...
...Wis. You work hard. You,ve developed a lot of r...e recognized within your company. And you just got...or downsized or bought out. Whatever. The bottom l...ale of upward and onward has taken a sudden lost-i...st a hypothetical situation, but I,m seeing it mor...
... Alfalight, Inc., a University of Wisconsin-Madiso... received a research and development contract wort...n Adelphi, Md. The 12-month program will focus on ...ultimode diode laser source with an output of one ...nd monolithic solid-state laser that use a semicon...
Other Biology Technology:Cedara acquisition costs hit Merge Technologies numbers 2When doing a good job isn't good enough 2When doing a good job isn't good enough 3Alfalight awarded $4.5 million Army Research contract 2
SuperFreeze Peroxidase Conjugate Stabilizer from Pierce Biotechnology, Inc.
SA-HRP Dilution Buffer, 1L from Pierce Biotechnology, Inc.
...n optimized for the analysis of SearchLight® ...software to quickly and accurately locate and quan...or each section of a slide. SearchLight® Arra...ate standard ELISA analysis features, including cu...
...ated hybridization of microarrays on slides. The H...ffer researchers improved reproducibility, superio...orm a wide range of applications. Incubations may...up to 99C. The possibility of 6 on-board reagents ...
Biology Products: